肥猫发发
2021-04-16
Diamond hand
Why Zomedica Stock Plunged Thursday
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":370068988,"tweetId":"370068988","gmtCreate":1618536952944,"gmtModify":1634292248737,"author":{"id":3562230741987077,"idStr":"3562230741987077","authorId":3562230741987077,"authorIdStr":"3562230741987077","name":"肥猫发发","avatar":"https://static.tigerbbs.com/3fc7372e5d9e18b752cc26cb4b2233d3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Diamond hand</p></body></html>","htmlText":"<html><head></head><body><p>Diamond hand</p></body></html>","text":"Diamond hand","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/370068988","repostId":1104323307,"repostType":4,"repost":{"id":"1104323307","kind":"news","pubTimestamp":1618534802,"share":"https://www.laohu8.com/m/news/1104323307?lang=&edition=full","pubTime":"2021-04-16 09:00","market":"us","language":"en","title":"Why Zomedica Stock Plunged Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1104323307","media":"Motley Fool","summary":"Initial sales of a key product may be lower than investors were hoping for.\nWhat happened\nShares of ","content":"<p>Initial sales of a key product may be lower than investors were hoping for.</p>\n<p><b>What happened</b></p>\n<p>Shares of <b>Zomedica Pharmaceuticals</b> (NYSEMKT:ZOM) fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy.</p>\n<p><b>So what</b></p>\n<p>Zomedica will build out its internal sales team as it transitions away from its current distributor-based approach. CEO Robert Cohen said the move was precipitated by \"changes at our current distributor that we believe have impacted its ability to market our products effectively.\" Those words likely startled investors, many of whom decided to sell their shares.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2801a170fd507ea28b362a0630d8590b\" tg-width=\"2000\" tg-height=\"1232\"><span>ZOMEDICA'S STOCK PRICE DROPPED SHARPLY ON THURSDAY. IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>To be fair, Cohen said that while the shift might negatively impact near-term sales of its Truforma diagnostic platform for dogs and cats, it could have some long-term benefits.</p>\n<p>\"While this effort may slow initial sales of Truforma, we have taken this action now to avoid any disruption to our customers and to provide a stronger foundation on which to build the marketing and sales of both Truforma and any future products developed or acquired by Zomedica,\" Cohen said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Zomedica recorded its first veterinarian sale of Truforma in mid-March. The diagnostic platform lies at the core of the company's commercial strategy and is likely to remain its only revenue generator for some time. Investors, in turn, are understandably concerned about a potential slower sales rollout for Truforma.</p>\n<p>That said, Zomedica raised roughly $200 million via a share offering in February, so it has the cash it needs to ramp up its sales team. Shareholders will need to be patient with Zomedica's new approach, but if Truforma is the game changer management says it is, then sales should eventually materialize.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Zomedica Stock Plunged Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Zomedica Stock Plunged Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 09:00 GMT+8 <a href=https://www.fool.com/investing/2021/04/15/why-zomedica-stock-plunged-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Initial sales of a key product may be lower than investors were hoping for.\nWhat happened\nShares of Zomedica Pharmaceuticals (NYSEMKT:ZOM) fell 13.7% on Thursday after the veterinary health company ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/why-zomedica-stock-plunged-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/15/why-zomedica-stock-plunged-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104323307","content_text":"Initial sales of a key product may be lower than investors were hoping for.\nWhat happened\nShares of Zomedica Pharmaceuticals (NYSEMKT:ZOM) fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy.\nSo what\nZomedica will build out its internal sales team as it transitions away from its current distributor-based approach. CEO Robert Cohen said the move was precipitated by \"changes at our current distributor that we believe have impacted its ability to market our products effectively.\" Those words likely startled investors, many of whom decided to sell their shares.\nZOMEDICA'S STOCK PRICE DROPPED SHARPLY ON THURSDAY. IMAGE SOURCE: GETTY IMAGES.\nTo be fair, Cohen said that while the shift might negatively impact near-term sales of its Truforma diagnostic platform for dogs and cats, it could have some long-term benefits.\n\"While this effort may slow initial sales of Truforma, we have taken this action now to avoid any disruption to our customers and to provide a stronger foundation on which to build the marketing and sales of both Truforma and any future products developed or acquired by Zomedica,\" Cohen said in a press release.\nNow what\nZomedica recorded its first veterinarian sale of Truforma in mid-March. The diagnostic platform lies at the core of the company's commercial strategy and is likely to remain its only revenue generator for some time. Investors, in turn, are understandably concerned about a potential slower sales rollout for Truforma.\nThat said, Zomedica raised roughly $200 million via a share offering in February, so it has the cash it needs to ramp up its sales team. Shareholders will need to be patient with Zomedica's new approach, but if Truforma is the game changer management says it is, then sales should eventually materialize.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/370068988"}
精彩评论